India’s Ranbaxy To Continue Acquisitions Despite Daiichi Purchase
This article was originally published in PharmAsia News
Executive Summary
Despite a pending buyout by Japan's Daiichi Sankyo, India's Ranbaxy Laboratories plans to follow through on acquisition plans made before the Daiichi offer. Ranbaxy CEO Malvinder Mohan Singh said that even as a Daiichi subsidiary, Ranbaxy would continue to acquire other companies and attempt to grow as a drug maker with separate ownership and management. Singh also denied assertions the merger would harm Ranbaxy's business in India. He said changes in shareholders and foreign ownership would not make Ranbaxy a non-Indian company. (Click here for more